Charles Swanton Selected Research

Chromosomal Instability (Chromosome Stability)

10/2021	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution.
10/2019	A clonal expression biomarker associates with lung cancer mortality.
1/2018	Chromosomal instability drives metastasis through a cytosolic DNA response.
8/2015	Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
11/2014	Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.
6/2013	Taxane benefit in breast cancer--a role for grade and chromosomal stability.
2/2012	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.
11/2010	Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
10/2009	Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy.
5/2009	Chromosomal instability determines taxane response.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles Swanton Research Topics

Disease

125	Neoplasms (Cancer) 11/2022 - 11/2004
25	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2006
16	Lung Neoplasms (Lung Cancer) 09/2020 - 01/2013
11	Renal Cell Carcinoma (Grawitz Tumor) 11/2021 - 07/2009
11	Chromosomal Instability (Chromosome Stability) 10/2021 - 04/2006
11	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 07/2006
9	Melanoma (Melanoma, Malignant) 01/2021 - 03/2013
7	COVID-19 01/2022 - 01/2020
7	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 04/2006
6	Disease Progression 11/2022 - 01/2006
6	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2010
5	Adenocarcinoma of Lung 01/2022 - 11/2015
3	Prostatic Neoplasms (Prostate Cancer) 06/2022 - 01/2012
3	Genomic Instability 01/2021 - 10/2012
3	Infections 01/2021 - 01/2020
3	Ovarian Neoplasms (Ovarian Cancer) 05/2009 - 06/2007
2	Residual Neoplasm 01/2022 - 06/2007
2	Bites and Stings (Sting) 01/2021 - 01/2018
2	Carcinogenesis 01/2021 - 03/2015
2	Stomach Neoplasms (Stomach Cancer) 01/2019 - 11/2013
2	Glioma (Gliomas) 05/2017 - 03/2013
2	Aneuploidy (Aneuploid) 01/2017 - 01/2017
2	Triple Negative Breast Neoplasms 12/2016 - 04/2010
2	Polyploidy 02/2012 - 06/2007
1	Microsatellite Instability 01/2022
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Epilepsy (Aura) 01/2021
1	Malignant Mesothelioma 01/2021
1	Cytokine Release Syndrome 01/2021

Drug/Important Bio-Agent (IBA)

21	Biomarkers (Surrogate Marker)IBA 10/2021 - 01/2010
20	Pharmaceutical PreparationsIBA 01/2020 - 06/2007
15	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2004
15	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 05/2011
9	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2006
8	RNA (Ribonucleic Acid)IBA 11/2022 - 04/2012
8	Immune Checkpoint InhibitorsIBA 01/2022 - 03/2016
8	Estrogen ReceptorsIBA 09/2014 - 05/2009
7	AntibodiesIBA 01/2022 - 01/2017
6	Biological ProductsIBA 01/2022 - 05/2011
6	ErbB Receptors (EGF Receptor)IBA 01/2018 - 01/2011
5	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2021 - 12/2013
5	AntigensIBA 01/2021 - 12/2013
5	PlatinumIBA 01/2021 - 10/2009
5	Paclitaxel (Taxol)FDA LinkGeneric 02/2012 - 06/2007
4	Phosphotransferases (Kinase)IBA 11/2020 - 08/2007
4	Tamoxifen FDA LinkGeneric 04/2013 - 02/2008
4	Taxoids (Taxanes)IBA 11/2010 - 04/2006
3	Circulating Tumor DNAIBA 10/2021 - 02/2016
3	EnzymesIBA 10/2021 - 07/2015
3	pertuzumabIBA 01/2021 - 01/2018
3	human ERBB2 proteinIBA 01/2018 - 11/2013
3	Cytotoxins (Cytolysins)IBA 05/2016 - 06/2007
3	taxaneIBA 06/2013 - 04/2006
3	CeramidesIBA 02/2012 - 06/2007
2	Messenger RNA (mRNA)IBA 11/2022 - 01/2021
2	Cell-Free Nucleic AcidsIBA 06/2022 - 12/2017
2	COVID-19 VaccinesIBA 01/2022 - 01/2021
2	VaccinesIBA 12/2021 - 12/2021
2	Neutralizing AntibodiesIBA 12/2021 - 12/2021
2	CarcinogensIBA 12/2021 - 10/2014
2	NivolumabIBA 11/2021 - 10/2021
2	CytosineIBA 10/2021 - 07/2015
2	cyclopropapyrroloindoleIBA 01/2021 - 01/2020
2	SteroidsIBA 01/2021 - 08/2017
2	Cyclin DIBA 01/2021 - 01/2004
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2021 - 01/2004
2	ChromatinIBA 01/2021 - 01/2017
2	Carisoprodol (Soma)FDA LinkGeneric 01/2021 - 10/2020
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 01/2021 - 01/2018
2	Adenosine Triphosphate (ATP)IBA 01/2019 - 06/2012
2	IgG Receptors (Fc gamma RI)IBA 01/2018 - 01/2017
2	NucleotidesIBA 10/2015 - 10/2012
2	TOR Serine-Threonine KinasesIBA 04/2015 - 11/2011
2	AnthracyclinesIBA 11/2010 - 11/2006
2	Estrogen Receptor Modulators (Antiestrogen)IBA 02/2010 - 02/2008
2	Carboplatin (JM8)FDA LinkGeneric 10/2009 - 05/2009
1	SolutionsIBA 06/2022
1	atezolizumabIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 12/2021
1	B7-H1 AntigenIBA 10/2021
1	pembrolizumabIBA 10/2021
1	AsbestosIBA 01/2021
1	Adenosine (Adenocard)FDA LinkGeneric 01/2021
1	BNT162 VaccineIBA 01/2021
1	mRNA VaccinesIBA 01/2021
1	CytokinesIBA 01/2021
1	UbiquitinIBA 01/2021
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021

Therapy/Procedure

70	Therapeutics 01/2022 - 11/2004
15	Immunotherapy 01/2022 - 07/2009
12	Drug Therapy (Chemotherapy) 01/2021 - 06/2007
11	Precision Medicine 10/2021 - 03/2012
3	Neoadjuvant Therapy 10/2021 - 04/2010
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2020 - 10/2016
2	Adjuvant Chemotherapy 01/2017 - 02/2012
2	Castration 01/2017 - 01/2012
1	Long-Term Care 01/2021